SBIR/STTR Research Award

Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device

Award identifier e9964909b3c222e30c436471476810badb691afc3f6a9e47fadbcdc46b615226Awarding agency Department of Defense · Office for Chemical and Biological Defense

Award amount

$99,982

Program and phase

SBIR · Phase I

Award year

2010

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Office for Chemical and Biological Defense
Recipient company
Physical Optics Corporation
Proposal award date
2010-05-17
Contract end date
2010-11-16
UEI
DG3AB4E8R4D8
Solicitation number
2010.1
Topic code
CBD10-102

Research abstract

To address the CBD need for improved formulations to enhance the ease of use and bioavailability of antisense therapeutics, Physical Optics Corporation (POC) proposes to develop a Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device (MATEN). This proposed system is based on a new dry powder formulation and a novel design of an inhaler that uses in-house developed mature components. POC’s innovations in the nanocarrier (NC) construct and in the design of the inhaler, which is capable of delivering a single dose from the MATEN during one deep and slow inspiration, will enhance the bioavailability for antisense therapeutics that is necessary for the prophylaxes and early treatment of warfighters against emerging bio-warfare threats. As a result, this technology offers a formulation that is stable at ambient temperature, minimizes the potential for introduction of immunogenic materials and the bulk and complexity of dispensing, and which directly addresses the requirements of the Transformational Medical Technologies Initiative (TMTI) program. In Phase I, POC will demonstrate the feasibility of the MATEN by demonstrating product stability and establishing enhanced bioavailability in an animal model. In Phase II, POC will optimize candidate formulation for maximum bioavailability and conduct initial pharmacokinetic and pharmacodynamic studies in an animal model.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

1,933 SBIR/STTR records share this UEI (1986–2021). Reported award amounts total $549,686,800. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Defense, Department of Energy, National Aeronautics and Space Administration, Department of Health and Human Services, National Science Foundation, Department of Homeland Security

Contractor profile

PHYSICAL OPTICS CORPORATION

Historical federal award activity, when published, is on that contractor profile. Matched by UEI only.

Agency intelligence

Department of Defense

NAICS intelligence

This classification comes from the contractor profile, not from the SBIR award record.

Contractor industry classification NAICS 541512

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.